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Oxypurinol-Speciﬁc T Cells Possess Preferential
TCR Clonotypes and Express Granulysin in
Allopurinol-Induced Severe Cutaneous Adverse
Reactions
Wen-Hung Chung1,2,6, Ren-You Pan3,6, Mu-Tzu Chu4, See-Wen Chin1,2, Yu-Lin Huang1,2, Wei-Chi Wang5,
Jen-Yun Chang5 and Shuen-Iu Hung3,4
Allopurinol, a ﬁrst-line drug for treating gout and hyperuricemia, is one of the leading causes of severe
cutaneous adverse reactions (SCARs). To investigate the molecular mechanism of allopurinol-induced SCAR, we
enrolled 21 patients (13 Stevens–Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) and 8 drug reaction
with eosinophilia and systemic symptoms (DRESS)), 11 tolerant controls, and 23 healthy donors. We performed
in vitro T-cell activation assays by culturing peripheral blood mononuclear cells (PBMCs) with allopurinol,
oxypurinol, or febuxostat and measuring the expression of granulysin and IFN-γ in the supernatants of cultures.
TCR repertoire was investigated by next-generation sequencing. Oxypurinol stimulation resulted in a signiﬁcant
increase in granulysin in the cultures of blood samples from SCAR patients (n= 14) but not tolerant controls
(n= 11) or healthy donors (n= 23). Oxypurinol induced T-cell response in a concentration- and time-dependent
manner, whereas allopurinol or febuxostat did not. T cells from patients with allopurinol–SCAR showed no
crossreactivity with febuxostat. Preferential TCR-V-β usage and clonal expansion of speciﬁc CDR3 (third
complementarity-determining region) were found in the blister cells from skin lesions (n= 8) and oxypurinol-
activated T-cell cultures (n= 4) from patients with allopurinol–SCAR. These data suggest that, in addition to
HLA-B*58:01, clonotype-speciﬁc T cells expressing granulysin upon oxypurinol induction participate in the
pathogenesis of allopurinol-induced SCAR.
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INTRODUCTION
Allopurinol, a xanthine oxidase inhibitor, is currently a ﬁrst-
line drug for the treatment of gout and hyperuricemia (Braden
et al., 1994). Although generally well tolerated, allopurinol is
associated with severe cutaneous adverse reactions (SCARs)
that include drug rash with eosinophilia and systemic
symptoms (DRESS), Stevens–Johnson syndrome (SJS), and
toxic epidermal necrosis (TEN) (Espiritu et al., 1976; Braden
et al., 1994; Ramasamy et al., 2013). We ﬁrst reported a
strong association between the HLA-B*58:01 allele and
allopurinol-induced SCAR in Han Chinese, and this associa-
tion was further validated in different populations (Hung et al.,
2005; Kaniwa et al., 2008; Lonjou et al., 2008; Tassaneeyakul
et al., 2009; Phillips and Mallal, 2010; Kang et al., 2011).
Although the strength of association was very strong, the
positive predictive value of HLA-B*5801 for allopurinol-SCAR
was low (∼2.7%), indicating that other factors also participate
in the pathogenesis (Hung et al., 2005). We proposed that, in
addition to HLA-B*58:01, other immune receptors such as
TCRs are involved in the induction of the catastrophic
immune response seen in allopurinol–SCAR.
SCAR is thought to involve drug-speciﬁc T cells (Posadas
et al., 2002; Roujeau, 2006). The conventional lympho-
cyte transformation test (LTT) is the most widely used in vitro
test to examine the causative drugs of T cell–mediated
hypersensitivity (Pichler and Tilch, 2004). However, the
sensitivity of LTT is very low for SCAR, and examination of
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the causative drugs of SJS/TEN usually yields negative
results (Porebski et al., 2011). We previously showed that
granulysin, a secretory protein produced by cytotoxic T
lymphocytes and natural killer (NK) cells, played a key role in
the disseminated keratinocyte death in SJS/TEN (Chung et al.,
2008). It was recently suggested that a combination of
different assays examining the expression of granulysin,
granzyme B, and IFN-γ may improve the sensitivity of
in vitro T-cell activation assays for SCAR (Porebski et al.,
2013).
Febuxostat, an alternative xanthine oxidase inhibitor, is
recently introduced into the market, and it has been shown to
be well tolerated in patients with hyperuricemia (Becker et al.,
2005; Goldfarb et al., 2011). Currently, there is no report
demonstrating tolerability or possible crossreactivity of
allopurinol–SCAR T cells to febuxostat. In this study, we
performed in vitro T-cell activation assays measuring the
expression of granulysin and IFN-γ in the cultures to examine
the drug antigen of allopurinol–SCAR and to assess the
potential crossreactivity of T cells to febuxostat. Furthermore,
we analyzed the TCR repertoire of blister cells directly
from the skin lesions of allopurinol–SCAR patients and
compared their characteristics with those of in vitro
expanded T cells.
RESULTS
We enrolled 21 patients with allopurinol–SCAR (13 SJS/TEN
and 8 DRESS), 11 tolerant controls, and 23 healthy donors;
the demographic data are shown in Supplementary Table S1
online. The HLA-B*58:01 allele was present in 19 (90.48%)
of 21 patients with allopurinol–SCAR, 6 (54.55%) of 11
tolerant controls, and 15 (65.22%) of 23 healthy donors
(Supplementary Table S1 online).
Oxypurinol-induced T cells to release granulysin in allopurinol–
SCAR
We isolated peripheral blood mononuclear cells (PBMCs)
from 14 patients with allopurinol–SCAR, 11 tolerant controls,
and 23 healthy donors and performed in vitro T-cell activation
assays by culturing the PBMCs with allopurinol (10 and
100 μM), oxypurinol (10 and 100 μg ml− 1), febuxostat (4 and
40 μgml−1), tolerant drugs, or solvent control for 1 to
3 weeks. The levels of granulysin and IFN-γ in the super-
natants of cultures were measured by ELISA. No signiﬁcant
increase in granulysin levels was found in the PBMC cultures
with drugs at the physiological concentrations (i.e., allo-
purinol: 10 μM; oxypurinol: 10 μgml−1; febuxostat: 4 μgml−1;
Supplementary Figure S1 online). In comparison, robust
expression of granulysin was induced in the cultures when a
high concentration of oxypurinol (100 μgml−1, which is 10-
fold higher than the physiological level) was incubated with
the PBMCs from allopurinol–SCAR patients (n=14) for
2 weeks (Figure 1a–c and Supplementary Table S2 online).
There was no statistical change in granulysin levels in the
T-cell activation assays using PBMCs from 11 tolerant controls
(6 of 11 carrying HLA-B*58:01) or 23 healthy donors (15 of
23 carrying HLA-B*58:01) (Figure 1d–f and Supplementary
Table S2 and Supplementary Figure S2 online). Culturing
PBMCs with oxypurinol (100 μgml−1) for 2 weeks in a
granulysin-based T-cell activation assay showed a sensitivity
of 86% and a speciﬁcity of 91% for allopurinol–SCAR
(Figure 1g).
T cells of allopurinol–SCAR showed no crossreactivity to
febuxostat
The lack of a signiﬁcant increase in granulysin expression in
the PBMC cultures of allopurinol (10 or 100 μM) suggested
that the parent drug allopurinol was an ineffective antigen
(Figure 1a–c and Supplementary Table S2 and Supplementary
Figure S1 online). In addition, febuxostat did not induce
granulysin expression in the PBMC cultures, indicating
that the T cells of allopurinol–SCAR patients could not
crossreact to febuxostat (Figure 1a–c). We performed clinical
follow-up observations of allopurinol–SCAR patients receiv-
ing febuxostat. Of the 21 patients with allopurinol–SCAR, 10
patients (4 SJS, 1 TEN, and 5 DRESS) received febuxostat after
the SCAR episode. All 10 patients carried HLA-B*58:01
genotype. Febuxostat was prescribed to these patients in
order to control their severe hyperuricemia and gout. None
of the 10 patients developed recurrence of SCAR (DRESS or
SJS/TEN). Only one patient had pruritus at the beginning
of febuxostat treatment, but became tolerant to it after
continuous use.
IFN-γ is not a sensitive marker for examining the drug antigen of
allopurinol–SCAR
Expression of IFN-γ in the supernatants of PBMC cultures was
determined by ELISA. Although IFN-γ expression increased in
5 (38%) of the 13 samples after 1 week of incubation, there
was no statistical difference when compared with the solvent
control (Figure 2a). In addition, the expression of IFN-γ did not
reach signiﬁcant difference in all of the tested conditions
(Figure 2 and Supplementary Figure S3 online). These data
suggested that IFN-γ is not a sensitive marker for identifying
the drug antigen of allopurinol–SCAR in T-cell activation
assays. We also evaluated T-cell proliferation by conventional
LTT by measuring H3-thymidine incorporation; however,
the sensitivity of conventional LTT was too low for further
analysis (Supplementary Table S3 and Supplementary
Figure S4 online).
Immunophenotypes of oxypurinol-activated T cells
We investigated the immunophenotypes of in vitro expanded
cells by ﬂow cytometry and confocal microscopy. After
2 weeks of incubation with oxypurinol (100 μgml− 1), the
in vitro expanded CD45+ PBMCs consisted of 73.1% of CD3+
T lymphocytes and 5.8% of CD56+ NK cells (Figure 3a).
Oxypurinol stimulation resulted in an increase in CD3+
T cells expressing granulysin (accounting for 5.03% of CD45+
PBMCs), whereas allopurinol or febuxostat did not (Figure 3b
and c). The oxypurinol-expanded cells were composed
of 62.9% of CD4+ T cells and 17.2% of CD8+ T cells, and
there were increased cell populations representing CD8+
granulysin+ cells (4.05%), CD4+granulysin+ cells (6.84%),
and CD56+granulysin+ cells (27.21%) compared with the
cultures of solvent controls (Figure 3d). Confocal microscopy
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data further validated the ﬁnding that granulysin was expres-
sed by CD4+ T cells, CD8+ T cells, or NK cells (Figure 3e).
In addition, we examined the expression of CD107a
(LAMP-1), which is a marker for activated T cells and NK
cells (Betts et al., 2003), and found that the cell populations
representing CD4+CD107a+ T cells, CD8+CD107a+ T cells,
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Figure 1. Oxypurinol induced granulysin expression in peripheral blood mononuclear cell (PBMC) cultures from patients with allopurinol–severe
cutaneous adverse reaction (SCAR). PBMCs were isolated from 14 patients with allopurinol–SCAR and 11 tolerant controls. (a–f) Data of T-cell activation
assay obtained by incubating PBMCs with drugs at concentrations of 10-fold the therapeutic levels (i.e., allopurinol: 100 μM, oxypurinol: 100 μgml−1, and
febuxostat: 40 μgml−1) for 1 to 3 weeks. Granulysin expression in the culture supernatant was determined by ELISA, and the fold change in each sample
was normalized by that of solvent control. The bars represent the mean values of the fold changes of each group. A positive result of the assay was deﬁned
as a 2-fold increase in granulysin expression compared with the solvent control. The P-values were analyzed by one-sample t-test. (g) The sensitivity, speciﬁcity,
and crossreactivity of granulysin-based T-cell activation assay for allopurinol–SCAR.
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and CD56+CD107a+ NK cells increased after oxypurinol
stimulation (Supplementary Figure S5 online). These results
support that oxypurinol activated speciﬁc T cells to produce
granulysin in allopurinol–SCAR.
Preferential TCR clonotypes present in blister cells and
oxypurinol-expanded T cells from allopurinol–SCAR
We characterized the TCR repertoire of allopurinol–SCAR
using RNA isolated from (1) 8 samples of blister cells from the
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Figure 2. IFN-γ expression in peripheral blood mononuclear cell (PBMC) cultures from patients with allopurinol–severe cutaneous adverse reaction (SCAR) or
tolerant controls. PBMCs were isolated from 13 patients with allopurinol–SCAR and 11 tolerant controls. (a–f) Data of T-cell activation assay obtained by
incubating PBMCs with drugs at concentrations of 10-fold the therapeutic levels (i.e., allopurinol: 100 μM, oxypurinol: 100 μgml−1, febuxostat: 40 μgml−1) for 1
to 3 weeks. The expression of IFN-γ in the culture supernatant was determined by ELISA, and the fold change of IFN-γ in each sample was normalized by the
solvent control. The bars represent the mean values of fold changes of each group. A positive result of the assay was deﬁned as a 2-fold increase in IFN-γ
expression compared with the solvent control. The P-values were analyzed by one-sample t-test. (g) The sensitivity, speciﬁcity, and crossreactivity of the IFN-γ-
based T-cell activation assay for allopurinol–SCAR.
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skin lesions of allopurinol–SJS/TEN patients, (2) 8 samples of
PBMCs from healthy donors, (3) 4 samples of oxypurinol-
expanded PBMCs and 4 samples of solvent control-cultured
PBMCs from the allopurinol–SCAR cases, and (4) 2 samples
of oxypurinol-cultured PBMCs from tolerant controls
(Supplementary Table S1 online). The data of TRBV (T-cell
receptor β variable), TRBJ (T-cell receptor β joining) usages,
and 10 most common TCR clonotypes in each sample
are summarized in Figures 4 and 5 and Supplementary
Tables S4 and S5 and Supplementary Figure S6 online.
Compared with the TRBV usage of PBMCs from the 8 healthy
donors, a signiﬁcant increase in the frequencies of TRBV3-1,
5–1, 9, and 29-1 was noticed in the blister cells and
oxypurinol-expanded T cells from the allopurinol–SCAR
patients (Po0.05; Figure 4). Expansion of speciﬁc TCRβ
CDR3 (third complementarity-determining region) clonotypes
was found in blister cells or oxypurinol-cultured PBMCs from
patients with allopurinol–SCAR (Figure 5). For example, the
individual CDR3 clonotype “SVLIEGTQY” of TRBV29-1
accounted for 16.07% of all CDR3 clonotypes of case 1,
“ASSQDLTGNTIY” of TRBV3-1 for 46.08% of case 4,
and “ASSPRDFSYEQY” of TRBV9 for 18.83% of case 6
(Figure 5a). Table 1 lists the predominant TCRβ CDR3
clonotypes with frequencies 43%. Although the expanded
repertoire differed from case to case, several CDR3
clonotypes identiﬁed from the blister cells of some patients
showed high similarity (Supplementary Figure S7 online). In
comparison, these CDR3 clonotypes were absent or detected
at frequencies of o0.002% in the CDR3 clonotypes of the
PBMCs from healthy donors (Table 1 and Figure 5). These
data revealed that blister cells and oxypurinol-expanded
T cells possessed preferential TCR clonotypes in allopurinol–
SCAR.
DISCUSSION
Despite low incidence of SCAR, the mortality rate is
∼10% for SJS, 30% for SJS/TEN overlap, and 50% for TEN
(Roujeau and Stern, 1994; Roujeau et al., 1995; Sekula
et al., 2013). Different methods and techniques have been
used to identify the causative drug and avoid the recurrent
induction of SCAR. These include patch tests (Barbaud
et al., 2013), LTTs (Pichler and Tilch, 2004), cytokine
release tests, and delayed reading of intradermal tests
(Macías et al, 2007). However, the results of these tests
were often negative for allopurinol-related SCAR (Porebski
et al., 2013). Here we show that a granulysin-based T-cell
activation assay validated oxypurinol as the drug antigen in
allopurinol–SCAR with high speciﬁcity and sensitivity. The
oxypurinol-speciﬁc T cells could be expanded in vitro from
the blood samples of patients with allopurinol–SCAR,
possessed speciﬁc CDR3 clonotypes, and expressed granuly-
sin upon induction. Oxypurinol-speciﬁc T cells might be very
few in the blood samples of allopurinol–SCAR patients in the
recovery stage, and a 2-week in vitro culture is required for
detecting the secondary activation of oxypurinol-speciﬁc
T cells.
The HLA-B*58:01 is a genetic marker of allopurinol–SCAR
and has been proposed to present drug antigen to T cells
for the induction of drug hypersensitivity (Hung et al., 2005;
Pan et al., 2014; Lin et al., 2015). Recent studies using
PBMCs mostly from healthy donors with HLA-B*58:01
showed that oxypurinol directly activated naive T cells via
the preferential use of HLA-B*58:01 (Yun et al., 2013, 2014).
The in vitro expanded T cells reacted immediately to the
drug antigen and bypassed intracellular antigen processing,
consistent with the “pharmacological interaction with
immune receptors” (p-i) concept (Yun et al., 2013, 2014). In
this study, we cultured the blood samples of allopurinol–
SCAR patients and found that oxypurinol induced T-cell
activation in a dose-dependent manner, consistent with
a recent report (Yun et al., 2013). However, our PBMCs
from tolerant controls or healthy donors carrying HLA-
B*58:01 failed to activate T cells. We found that the TCR
repertoire of PBMCs of healthy donors or oxypurinol-cultured
cells from tolerant controls carrying HLA-B*58:01 showed
polyclonal and high diversity. Our results suggested that
the presence of high concentrations of oxypurinol and the
HLA-B*58:01 risk allele was insufﬁcient to induce speciﬁc
T-cell activation in allopurinol–SCAR. These data were
consistent with epidemiologic observations showing that the
incidence of allopurinol–SCAR is very low, and most
individuals carrying HLA-B*58:01 are tolerant to allopurinol
administration.
Different mechanisms of HLA-associated drug hyper-
sensitivity have been described (Yun et al., 2012; Pan et al.,
2014). Abacavir hypersensitivity is associated with the
HLA-B*57:01 allele with a positive predictive value of
∼55% in Caucasians (Mallal et al., 2002; Hetherington
et al., 2002). Abacavir hypersensitivity has been explained by
the “altered peptide repertoire hypothesis,” in which abacavir
may change the shape and chemistry of the antigen-binding
cleft of HLA-B*57:01, thereby altering the repertoire of
endogenous peptides (Illing et al., 2012; Ostrov et al.,
2012). The in vitro abacavir-activated T cells showed
heterogeneous and polyclonal TCR usages, and the HLA-
B*57:01 allele, rather than TCR, has been proposed to
have the major role in abacavir hypersensitivity (Adam et al.,
2012; Bharadwaj et al., 2012; Illing et al., 2012; Ostrov et al.,
2012). Another example is the association between
carbamazepine-induced SJS/TEN and the HLA-B*15:02 allele
that has a very low positive predictive value (Chung et al.,
2004). Our previous study reported that HLA-B*15:02
possessed afﬁnity toward carbamazepine or its metabolite
and was able to present the drug antigens to T cells via
“pharmacological interaction with immune receptors”
(p-i) mechanism (Wei et al., 2012). Shared and restricted
TCR clonotypes were noted in the in vitro expanded T cells
from PBMCs of carbamazepine–SJS/TEN patients (Ko et al.,
2011). In this study, we found preferential TCR usage,
clonal expansion, and similar CDR3 clonotypes in the
blister cells of patients with allopurinol–SCAR. However, we
did not observe identical TCR clonotypes in the samples
of allopurinol–SCAR. The TCR repertoire of allopurinol–
SCAR seems more complex and different from that of
carbamazepine–SJS/TEN (Ko et al., 2011). In addition, the
in vitro expansion of antigen-speciﬁc T cells may distort
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the T-cell repertoire (Koning et al., 2014). More experiments
and samples directly isolated from the skin lesions are needed
to investigate the mechanism of SCAR.
In addition to the predisposition of susceptible HLA
alleles and the induction of speciﬁc TCR clonotypes,
deﬁciency of drug metabolism or impaired drug clearance
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has been linked to SCAR (Chung et al., 2014a). The risk
factors for allopurinol–SCAR include HLA-B*58:01 allele,
renal insufﬁciency, and delayed clearance of oxypurinol
(Chung et al., 2014b). Chronic renal diseases may delay
the clearance of oxypurinol and increase the plasma
levels of the drug antigen. In this study, we reported that
supraphysiological concentrations of oxypurinol induced
speciﬁc T-cell activation in PBMC cultures from patients
with allopurinol–SCAR. However, this does not reﬂect
physiological conditions, where oxypurinol may work with
a number of other cofactors in a synergistic manner to
become more immunogenic for low-avidity T cells in
susceptible subjects.
In summary, our data demonstrated that granulysin-based
T-cell activation assay is a sensitive method for examining the
causative drug of allopurinol–SCAR. We propose that the
mechanism underlying the pathogenesis of allopurinol-
induced SCAR involves both HLA-B*58:01 and clonotype-
speciﬁc T cells with a dose-dependent response to
oxypurinol. T cells from patients with allopurinol–SCAR did
not crossreact to febuxostat. These data suggest that
clonotype-speciﬁc T cells expressing granulysin upon oxypur-
inol induction participate in the pathogenesis of allopurinol-
induced SCAR.
MATERIALS AND METHODS
Patient enrollment and sample collection
Patients with allopurinol–SCAR were recruited at the Chang Gung
Memorial Hospital Health System in Taiwan between 2011 and
2013. SJS/TEN or DRESS diagnoses were based on the deﬁnition
of the RegiSCAR study group (Auquier-Dunant et al., 2002;
Kardaun et al., 2007). Only patients with a probable or a deﬁnite
diagnosis of SJS/TEN or DRESS were enrolled in this study. The
Naranjo algorithm (Naranjo et al., 1981) and the algorithm of
drug causality assessment for SJS/TEN (ALDEN) (Sassolas et al., 2010)
were applied to identify the offending drug as allopurinol.
In addition, we enrolled 23 healthy donors and 11 tolerant
subjects who had received allopurinol for 46 months without
any adverse reactions. We collected the information, including
sex, age, indications for allopurinol use, duration and dose of
allopurinol exposure, and HLA-B genotyping results of the
enrolled subjects. HLA-B genotypes were determined by SeCore
HLA Sequence–based typing (Invitrogen, Life Technologies,
Carlsbad, CA). Approval for the study was obtained from the
institutional review board, and written informed consent was
obtained from each participant.
T-cell activation assay
PBMCs were isolated from the whole blood samples using Ficoll-
Paque (Pharmacia Fine Chemicals, Uppsala, Sweden) density
gradient centrifugation. PBMCs (1.0× 106 per well) were cultured
in 96-well microplates in RPMI-1640 medium (GIBCO Invitrogen,
Life Technologies, Carlsbad, CA) supplemented with 10% auto-
logous serum, IL-7 (1 ng ml− 1; Invitrogen), and the drugs for
examination at 37 °C in 5% CO2 for 1 to 3 weeks. Allopurinol,
oxypurinol (Sigma-Aldrich, Munich, Germany), febuxostat (Teijin
Pharma, Tokyo, Japan), or tolerant drugs were diluted in the medium
to obtain a concentration reﬂecting the physiological therapeutic
level (noted as 1-fold or 10-fold; Brunton et al., 2011). Thus, cells
were incubated in the medium containing allopurinol (10 and
100 μM), oxypurinol (10 and 100 μgml− 1), febuxostat (4 and
40 μgml− 1), or tolerant drugs that had been used by the patients
for 43 months without any adverse reactions. In addition, the
solvent was added to the medium as the negative control, and
phytohemagglutinin at a concentration of 10 μgml− 1 was used as the
positive control. Culture supernatants were collected on days 7, 14,
and 21 for measuring the levels of granulysin using ELISAs (Chung
et al., 2008). Samples were analyzed in triplicate. The assay
sensitivity for granulysin was 1.56 ngml− 1. In addition, the levels
of IFN-γ in samples were measured using IFN-γ ELISA kits (Invitrogen,
Carlsbad, CA) with a sensitivity of 1.56 pgml− 1.
Lymphocyte transformation test
The culprit drugs of SCAR patients were tested by conventional LTT
using H3-thymidine incorporation (Pichler and Tilch, 2004). Brieﬂy,
PBMCs (1.0×106 cells per well) were cultured in 96-well U-bottom
plates containing medium in the presence of allopurinol, oxypurinol,
or febuxostat. After 6 days of culture, 1 μCi H3-thymidine was added for
an overnight incubation. The cells were harvested and H3-thymidine
incorporation was measured as counts per min (c.p.m.) on a Top-Count.
The proliferative response was calculated as the stimulation index: c.p.
m. of drug-treated cultures/c.p.m. of cultures with solvent control.
Stimulation index of 42 was considered as a positive response.
Flow cytometry, immunoﬂuorescence analysis, and confocal
microscopy
Flow cytometry was carried out using distinct ﬂuorochrome-
conjugated mAbs that recognize human CD3, CD4, CD8, CD45,
CD56 (Beckman Coulter, Fullerton, CA), CD107a (Ebioscience,
San Diego, CA), or intracellular granulysin (RB1) (BD Biosciences,
Bedford, MA). These mAbs were labeled with Alexa Fluor 488,
phycoerythrin-Texas Red (ECD), phycoerythrin-cyanine 5 (PC5), or
phycoerythrin-cyanin 7 (PC7). The cells were examined by means of
multicolor ﬂow cytometry on the Cytomics FC500 ﬂow cytometer
Figure 3. Oxypurinol-expanded T cells express granulysin. Peripheral blood mononuclear cells (PBMCs) from three patients (cases 13, 16, and 20) with
allopurinol–severe cutaneous adverse reaction (SCAR) were cultured with allopurinol (100 μM), oxypurinol (100 μgml−1), febuxostat (40 μgml−1), solvent
control, or phytohemagglutinin (PHA; 10 μgml−1) for 2 weeks. The immunophenotype of the cultured PBMCs was determined by ﬂow cytometry.
(a) Oxypurinol-expanded CD45+ PBMCs comprised CD3+ T lymphocytes (73.1%) and CD56+ natural killer (NK) cells (5.8%). (b and c) Frequencies of CD3+
granulysin+ T cells in the PBMC cultures with different drugs and controls. Data of c are expressed as mean± SD of three independent experiments (cases 13, 16,
and 20). (d) The oxypurinol-cultured CD3+ T cells from case 20 comprised CD4+ T lymphocytes (62.9%) and CD8+ T cells (17.2%). When comparing with
the solvent controls, there were increases in 4.05% in CD8+granulysin+ cells, 6.84% in CD4+granulysin+ cells, and 27.21% in CD56+granulysin+ cells.
(e) Photographs depicting oxypurinol-expanded cells expressing granulysin, CD4, CD8, and CD56. The blue color represented 4’,6-diamidino-2-phenylindole-
stained nuclei of cells. Scale bar=10 μm.
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(Beckman Coulter), and data were analyzed with the CXP software
(Beckman Coulter). Immunoﬂuorescence staining was performed
using mouse anti-CD4 (RPA-T4, Ebioscience), mouse anti-CD8
(RPA-T8, Ebioscience), mouse anti-CD56 (MEM-188, BioLegend,
Uithoorn, The Netherlands), rabbit anti-granulysin (H-130, Santa
Cruz Biotechnology, Santa Cruz, CA), and speciﬁc ﬂuorescence-
conjugated secondary antibodies (Molecular Probes, Eugene, OR).
The nuclei of cells were stained by 4’,6-diamidino-2-phenylindole.
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Figure 4. The T-cell receptor β variable (TRBV) gene usage in allopurinol–severe cutaneous adverse reaction (SCAR). TCR repertoire was analyzed using
RNA extracted from (a) eight samples of blister cells from skin lesions of allopurinol–Stevens–Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) patients,
(b) oxypurinol-cultured T cells from four patients with allopurinol–SCAR, and (c) peripheral blood mononuclear cells (PBMCs) from eight healthy donors.
Bars represent the mean values of the percentages of respective TRBV gene usage in the group of samples. The P-values were analyzed by Student’s t-test.
When compared with the TRBV usage of PBMCs from 8 healthy donors, the frequencies of TRBV3-1, 5-1, 9, and 29-1 were signiﬁcantly increased in the
blister cells and oxypurinol-cultured T cells from the allopurinol–SCAR patients (Po0.05).
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The Olympus FV1000 confocal microscope (Tokyo, Japan) and
FV10-ASW 3.1 viewer software were used for image analysis.
TCR repertoire investigation by next-generation sequencing
PCR ampliﬁcation and next-generation sequencing of the VDJ
junction and the rearranged CDR3 regions of TCR were performed
as previously described (Wang et al., 2010). Brieﬂy, RNA was
isolated from the blister cells and the oxypurinol-stimulated cultures
of PBMCs from the patients with allopurinol–SCAR. Multiple PCR
ampliﬁcations were carried out using a panel of TCR primers
speciﬁcally targeted to all the V and J regions of the TCRβ
(iRepertoire, Huntsville, AL). The complementary DNA library was
sequenced using Illumina Miseq system (San Diego, CA) or Roche
454 junior system (Branford, CT). The CDR3 interval of TCR
transcripts was identiﬁed as comprising all the amino acids between
the Y[YFLI]C at the 3′ end of the V gene segment and [FW]GXGT (X
represents any amino acid) within the J segments (Wang et al., 2010).
The TRBV, TRBJ, and CDR3 clonotypes were deﬁned according to
the ImMunoGeneTics (IMGT) information database (www.imgt.org),
as previously described (Yousﬁ Monod et al, 2004).
Statistical analysis
The fold changes of granulysin or IFN-γ expression in the culture
supernatant of PBMCs stimulated by allopurinol, oxypurinol,
febuxostat, or tolerant drugs were calculated by dividing the data
by the solvent control. Signiﬁcant difference between the groups was
analyzed by one-sample t-test or Student’s t-test. The sensitivity and
speciﬁcity were calculated according to the standard deﬁnitions. All
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Figure 5. TCRβ CDR3 (third complementarity-determining region) clonotypic analysis of T cells in allopurinol–severe cutaneous adverse reaction (SCAR). Pie
charts indicate the TCRβ CDR3 clonotypes of T cells from (a) blister cells of eight patients with allopurinol–Stevens–Johnson syndrome (SJS)/toxic epidermal
necrolysis (TEN), (b) peripheral blood mononuclear cells (PBMCs) of two representative healthy donors, (c) oxypurinol-cultured PBMCs from four patients with
allopurinol–SCAR, and (d) oxypurinol-cultured PBMCs from two tolerant controls. The amino-acid sequences of the 10 most common TCRβ CDR3 clonotypes of
each sample are listed, and the frequencies of the individual clonotypes are shown in the pie charts. Gray indicates other CDR3 clonotypes found in the sample,
in which the frequency of the individual CDR3 clonotype is o1%. Clonal expansion of speciﬁc CDR3 was noted in the samples of blister cells (a) and the
oxypurinol-cultured PBMCs from patients with allopurinol–SCAR (c) but not the PBMCs from healthy donors (b) or oxypurinol-cultured PBMCs from tolerant
controls (d).
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Table 1. The preferential TCRβ CDR3 clonotypes in blister cells and oxypurinol-expanded T cells from patients with
allopurinol-induced SCAR
Preferential CDR3 clonotypes in the blister cells
of 8 patients with allopurinol-SJS/TEN
Frequencies of the speciﬁc CDR3
in PBMCs of 8 healthy donors
Case no. Symptom CDR3 clonotypes TRBV TRBJ
Frequency
(%)
Speciﬁc CDR3
reads/total reads
Frequency
(%)
Speciﬁc CDR3 reads/
sum of the total reads
Case 1 TEN 1 SVLIEGTQY 29-1 2-5 16.07 419/2,608 0 0/6,369,051
2 ASSVLATSSYNEQF 5-6 2-1 5.45 142/2,608 0 0/6,369,051
3 ASSFGGSYEQY 5-6 2-7 3.60 94/2,608 0.000109 88/6,369,051
4 AWKDKLYNEQF 12-4 2-1 3.08 80/2,608 0 0/6369051
Case 2 TEN 1 ASRGGNTEAF 6-1 1-1 3.38 24,870/736,671 0.000188 155/6,369,051
Case 3 TEN 1 ASSSIGTENQPQH 28 1-5 4.20 27,778/661,129 0 0/6,369,051
2 ASRTDRTTNYGYT 4-2 1-2 3.45 22,790/661,129 0 0/6,369,051
3 ASSSGLAGDYNEQF 28 2-1 3.12 20,641/661,129 0 0/6,369,051
Case 4 TEN 1 ASSQDLTGNTIY 3-1 1-3 46.08 327,103/709,797 0 0/6,369,051
2 ATSPGTVETQY 15 2-5 11.03 78,292/709,797 0 0/6,369,051
3 ASSSTGGGLQETQY 28 2-5 3.51 24,881/709,797 0 0/6,369,051
Case 5 TEN 1 ASSFRRGNTDTQY 11-2 2-3 4.65 298/6,419 0.0007 7/6,369,051
2 SVEALTGEETQY 29-1 2-5 4.52 290/6,419 0 0/6,369,051
3 ASSLRRGNTDTQY 11-2 2-3 3.61 231/6,419 0 0/6,369,051
4 ASSPDQVDYRVNIQY 6-6 2-4 3.36 215/6,419 0 0/6,369,051
Case 6 SJS/TEN 1 ASSPRDFSYEQY 9 2-7 18.83 1,027/5,456 0.0005 5/6,369,051
2 ASSTDRVGNTIY 19 1-3 14.29 779/5,456 0 0/6,369,051
3 SVERASGSYNEQF 29-1 2-1 5.11 279/5,456 0 0/6,369,051
4 ASSANRGHEQY 7-6 2-7 3.46 188/5,456 0 0/6,369,051
Case 7 SJS/TEN 1 SVERLAGQETQY 29-1 2-5 14.00 166/1,187 0 0/6,369,051
2 SVVVAESSYNEQF 29-1 2-1 7.85 93/1,187 0 0/6,369,051
3 ASTLGYEQY 10-2 2-7 5.55 66/1,187 0.0016 15/6,3690,51
4 SVERLTGQETQY 29-1 2-5 4.80 57/1,187 0 0/6,369,051
5 SVEALAGEETQY 29-1 2-5 4.74 56/1,187 0 0/6,369,051
6 ASSQISDNYNEQF 14 2-1 3.22 38/1,187 0 0/6,369,051
Case 8 SJS 1 ASSPDSGGFSVQY 5-4 2-7 5.09 30,640/601,764 0 0/6,369,051
Preferential CDR3 clonotypes in the oxypurinol-expanded
T cells from PBMCs of 4 patients with allopurinol–SCAR
Frequencies of the speciﬁc CDR3
in the solvent-incubated control
Case no. Symptom CDR3 clonotypes TRBV TRBJ
Frequency
(%)
Speciﬁc CDR3 reads/
total CDR3 reads
Frequency
(%)
Speciﬁc CDR3 reads/
total CDR3 reads
Case 5 TEN 1 ASSLAPTDGYT 5-1 1-2 6.94 456/6,576 0 0/4,125
2 ASSPPSGADTQY 18 2-3 5.76 379/6,576 0 0/4,125
Case 7 SJS/TEN 1 AYDRGLTRDTQY 30 2-3 5.42 572/10,560 0 0/2,415
2 SVSGTDTQY 29-1 2-3 3.95 417/10,560 0 0/2,415
3 AWSVQGYEQY 30 2-7 3.10 327/10,560 1.2008 29/2,415
Case 15 DRESS 1 ASRPLGGSNQETQY 7-6 2-5 16.50 975/5,909 0 0/4,080
2 ATVVGPNYGYT 10-3 1-2 14.25 842/5,909 0.0490 2/4,080
3 ASRALSSYEQY 5-1 2-7 10.31 609/5,909 0 0/4,080
4 SAAGTGAEKLF 20-1 1-4 5.09 300/5,909 0 0/4,080
5 ASTQTTGSPLH 19 1-6 3.46 204/5,909 0 0/4,080
Case 21 DRESS 1 ASSLTWAVTEAF 27 1-1 5.80 34,484/594,957 0.0006 4/650,727
2 ASSLIVSSYEQY 7-2 2-7 4.73 28,153/594,957 0.0007 5/650,727
3 ASSFSDRNNQPQH 28 1-5 3.37 20,051/594,957 0 0/650,727
Abbreviations: CDR3, third complementarity-determining region; DRESS, drug reaction with eosinophilia and systemic symptom; PBMC, peripheral blood
mononuclear cell; SCAR, severe cutaneous adverse reaction; SJS, Stevens–Johnson syndrome; TEN, toxic epidermal necrolysis; TRBJ, T-cell receptor β joining;
TRBV, T-cell receptor β variable.
W-H Chung et al.
Oxypurinol-Speciﬁc T Cells in Allopurinol Hypersensitivity
2246 Journal of Investigative Dermatology (2015), Volume 135
P-values were two tailed, and a P-value of o0.05 was considered
statistically signiﬁcant. Statistical analyses were performed using
the SPSS software Version 18.0 (SPSS, Chicago, IL). The phylogenetic
tree of TCRβ CDR3 clonotypes was analyzed by the software
MATLAB version 8.1 (MathWorks, Natick, MA).
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